Mario Mandalà

Mario Mandalà

UNVERIFIED PROFILE

Are you Mario Mandalà?   Register this Author

Register author
Mario Mandalà

Mario Mandalà

Publications by authors named "Mario Mandalà"

Are you Mario Mandalà?   Register this Author

100Publications

3234Reads

42Profile Views

The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.

Cancer 2019 Nov 9;125(21):3776-3789. Epub 2019 Jul 9.

Unit of Medical Oncology, Department of Oncology and Hematology, Pope John XXIII Cancer Center Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32375DOI Listing
November 2019

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

N Engl J Med 2019 08 4;381(7):626-636. Epub 2019 Jun 4.

From Institut Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif (C.R.), Aix-Marseille University, Marseille (J.J.G.), and Assistance Publique-Hôpitaux de Paris Dermatology and Clinical Investigation Center, Unité 976, Université de Paris, Hôpital Saint-Louis, Paris (C.L.) - all in France; Moscow City Oncology Hospital, Moscow (D. Stroyakovskiy), and the Petrov Research Institute of Oncology, St. Petersburg (E.L.) - both in Russia; Przychodnia Lekarska Komed, Konin (B.K.), the University of Medical Sciences, Poznań (A.M.), and the Maria Skłodowska-Curie Institute-Oncology Center, Warsaw (P.R.) - all in Poland; the University Hospital Schleswig-Holstein, Kiel (A.H.), the Department of Dermatology, University of Tübingen, Tübingen (C.G.), University Hospital Essen, Essen (D. Schadendorf), and the German Cancer Consortium, Heidelberg (D. Schadendorf) - all in Germany; the Veneto Institute of Oncology, Padua (V.C.S.), and Papa Giovanni XXIII Hospital, Bergamo (M.M.) - both in Italy; the Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer (J.S.), and Sackler Medical School, Tel Aviv University, Tel Aviv (J.S.) - both in Israel; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine (I.B.); Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens (H.G.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); Mount Vernon Cancer Centre, Northwood, United Kingdom (P.D.N.); the University of California, Los Angeles, Los Angeles (A.R.); the University of Texas M.D. Anderson Cancer Center, Houston (M.A.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (K.T.F.); Novartis Pharma, Basel, Switzerland (P.B.); Novartis Pharmaceuticals, East Hanover, NJ (M.T., E.G., M.V.); and the Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904059DOI Listing
August 2019

Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAF mutated melanoma cells in vitro.

Cancer Cell Int 2019 28;19:223. Epub 2019 Aug 28.

1Division of Surgical Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 57, 56126 Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0938-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712666PMC
August 2019

Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.

Handb Exp Pharmacol 2018;249:129-143

Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2017_5DOI Listing
June 2019

Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives.

Am J Clin Dermatol 2019 Jun 8. Epub 2019 Jun 8.

Melanoma Unit, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00456-4
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00456-4DOI Listing
June 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

Rational combination of cancer immunotherapy in melanoma.

Virchows Arch 2019 Apr 14;474(4):433-447. Epub 2018 Dec 14.

Maria Sklodowska-Curie Institute, Oncology Center, Warsaw, Poland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00428-018-2506-y
Publisher Site
http://dx.doi.org/10.1007/s00428-018-2506-yDOI Listing
April 2019

Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.

Future Oncol 2019 Mar 14;15(9):967-977. Epub 2019 Jan 14.

Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0659
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0659DOI Listing
March 2019

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches.

Curr Oncol Rep 2018 09 14;20(11):86. Epub 2018 Sep 14.

Institute of Pathology, Azienda Ospedaliero Universitaria (AOU), Sassari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0733-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153571PMC
September 2018

Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.

Eur J Cancer 2018 05 17;95:130-132. Epub 2018 Mar 17.

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.019DOI Listing
May 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

Semin Cancer Biol 2018 02 2;48:91-103. Epub 2017 May 2.

Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1044579X173011
Publisher Site
http://dx.doi.org/10.1016/j.semcancer.2017.04.015DOI Listing
February 2018

[Pembrolizumab for the treatment of melanoma: updates and perspectives.]

Recenti Prog Med 2017 Dec;108(12):528-531

Oncologia Medica 2, Ospedale San Martino, Genova.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1701/2829.28585DOI Listing
December 2017

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

N Engl J Med 2017 11 10;377(19):1824-1835. Epub 2017 Sep 10.

From New York University Perlmutter Cancer Center, New York (J.W.); Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M. Mandala), Medical Oncology, National Cancer Institute, Milan (M.D.V.), Oncology Institute of Veneto Istituti di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M. Maio), Ospedale Policlinico San Martino, Genoa (P.Q.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; National and Kapodistrian University of Athens, Athens (H.J.G.); Hospital Clinic de Barcelona, Barcelona (A.M.A.), and General University Hospital Gregorio Marañón, Madrid (I.M.-R.) - both in Spain; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); Hospices Civils de Lyon, Pierre Bénite (S.D.), Aix-Marseille University, Hospital de la Timone, Marseille (J.-J.G.), Institut Universitaire du Cancer de Toulouse and Centre Hospitalier Universitaire (CHU), Toulouse (N.M.), Université Lille, INSERM Unité 1189, CHU Lille, Lille (L.M.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint Louis, Université Paris Diderot, Paris (C.L.) - all in France; Oncology Center Sf. Nectarie, Craiova, Romania (M. Schenker); Princess Margaret Cancer Centre, University of Toronto, Toronto (M.O.B.), and Cross Cancer Institute, Edmonton, AB (M. Smylie) - both in Canada; the Department of Oncology, University of Oxford, Oxford (M.R.M.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; Gallipoli Medical Research Foundation and University of Queensland, Queensland, VIC (V.A.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney (G.V.L.) - all in Australia; University of Colorado, Denver (R.G.); Winship Cancer Institute, Emory University School of Medicine, Atlanta (R.R.K.); Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); University of Washington, Seattle (S.B.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Nagoya University Graduate School of Medicine, Nagoya (K.Y.), and the National Cancer Center Hospital, Tokyo (N.Y.) - both in Japan; Seoul National University Hospital, Seoul, South Korea (T.M.K.); and Bristol-Myers Squibb, Princeton, NJ (V.P, J.S., A.Q.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709030DOI Listing
November 2017

Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.

Am J Clin Dermatol 2017 Oct;18(5):597-611

Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-017-0282-0DOI Listing
October 2017

BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.

Am J Kidney Dis 2017 Jul 24;70(1):145-150. Epub 2017 Feb 24.

IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy; Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy; Department of Biomedical and Clinical Sciences, University of Milan, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2016.12.013DOI Listing
July 2017

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Eur J Cancer 2017 07 11;79:176-184. Epub 2017 May 11.

Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.04.007DOI Listing
July 2017

Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.

Eur J Cancer 2017 06 14;78:70-81. Epub 2017 Apr 14.

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.03.012DOI Listing
June 2017

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.

Lab Invest 2017 02 19;97(2):166-175. Epub 2016 Dec 19.

Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.2016.132DOI Listing
February 2017

Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights.

Cancer Treat Rev 2016 Sep 29;49:1-12. Epub 2016 Jun 29.

Unit of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.06.009DOI Listing
September 2016

PD-L1 in melanoma: facts and myths.

Melanoma Manag 2016 Sep 22;3(3):187-194. Epub 2016 Aug 22.

Division of Pathological Anatomy, Department of Surgery & Translational Medicine, University of Florence, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt-2016-0013
Publisher Site
http://dx.doi.org/10.2217/mmt-2016-0013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096437PMC
September 2016

AKT-ions with a TWIST between EMT and MET.

Oncotarget 2016 Sep;7(38):62767-62777

Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308764PMC
September 2016

Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling.

Physiol Rev 2016 07;96(3):805-29

Department of Biomedicine, University Hospital Basel, Basel, Switzerland; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy; Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China; and Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://physrev.physiology.org/content/physrev/96/3/805.full.
Web Search
http://dx.doi.org/10.1152/physrev.00024.2015DOI Listing
July 2016

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2016 Apr 10;100:88-98. Epub 2016 Feb 10.

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.02.001DOI Listing
April 2016

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

Future Oncol 2015 ;11(9):1355-62

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.55DOI Listing
February 2016

The complex management of atypical Spitz tumours.

Pathology 2016 Feb 16;48(2):132-41. Epub 2016 Jan 16.

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2015.12.003DOI Listing
February 2016

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Jun 11.

Department of Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research, 4058 Basel, Switzerland (GX, FT, BAH); Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland (GX, AZ, AW); Unit of Clinical and Translational Research, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, 24100 Bergamo, Italy (MM); Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, 50134 Florence, Italy (DM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv171DOI Listing
July 2015

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Mod Pathol 2015 Apr 24;28(4):487-97. Epub 2014 Oct 24.

Unit of Medical Oncology, Division of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2014.137DOI Listing
April 2015

Immunohistochemistry for an improved clinical workflow in the era of personalized melanoma therapy?

Melanoma Manag 2015 Feb 25;2(1):5-8. Epub 2015 Feb 25.

Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.27DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094605PMC
February 2015

Nras in melanoma: targeting the undruggable target.

Crit Rev Oncol Hematol 2014 Nov 12;92(2):107-22. Epub 2014 Jun 12.

Division of Pathological Anatomy, Department of Surgery and Translational Medicine, University of Florence, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10408428140008
Publisher Site
http://dx.doi.org/10.1016/j.critrevonc.2014.05.005DOI Listing
November 2014

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

N Engl J Med 2014 Nov 29;371(20):1867-76. Epub 2014 Sep 29.

From Royal Marsden Hospital, London (J.L.); Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Azienda Ospedaliera Universitaria Senese, Siena (M. Maio), and Papa Giovanni XXIII Hospital, Bergamo (M. Mandalà) - all in Italy; Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.), Centre Hospitalier Lyon Sud, Pierre-Bénite (L.T.), and Hôpital Saint André, Bordeaux (C.D.) - all in France; Princess Alexandra Hospital, Woolloongabba, QLD (V.A.), and Peter MacCallum Cancer Centre, Melbourne, VIC (G.A.M.) - both in Australia; National Institute of Oncology, Budapest, Hungary (G.L.); N.N. Blokhin Russian Cancer Research Center, Moscow (L.D.), and Moscow City Oncology Hospital 62, Krasnogorsk (D.S.) - both in Russia; Hospital Universitario Virgen Macarena, Seville, Spain (L.C.-M.); University of Tübingen, Tübingen, Germany (C.G.); Genentech, South San Francisco, CA (M.A.S., I.C., N.C., S.P.H.); and Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, Los Angeles (A.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1408868DOI Listing
November 2014

A prospective study on survival in cancer patients with and without venous thromboembolism.

Intern Emerg Med 2014 Aug 14;9(5):559-67. Epub 2013 Aug 14.

Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-013-0985-zDOI Listing
August 2014

Tissue prognostic biomarkers in primary cutaneous melanoma.

Virchows Arch 2014 Mar 1;464(3):265-81. Epub 2014 Feb 1.

Unit of Clinical and Translational Research, Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-013-1526-xDOI Listing
March 2014

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Crit Rev Oncol Hematol 2014 Jan 28;89(1):140-65. Epub 2013 Aug 28.

Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.08.002DOI Listing
January 2014

Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action.

Crit Rev Oncol Hematol 2013 Nov 3;88(2):318-37. Epub 2013 Jul 3.

Medical Oncology Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.06.002DOI Listing
November 2013

Targeting BRAF in melanoma: biological and clinical challenges.

Crit Rev Oncol Hematol 2013 Sep 15;87(3):239-55. Epub 2013 Feb 15.

Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.01.003DOI Listing
September 2013

Adjuvant therapy in breast cancer and venous thromboembolism.

Thromb Res 2012 Oct;130 Suppl 1:S66-70

Unit of Medical Oncology, Ospedali Riuniti, 24100 Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2012.08.280DOI Listing
October 2012

Is the pooled analysis of the north central cancer treatment group phase III trials N9741 and N9841 biased?

J Clin Oncol 2012 May 2;30(15):1894-5; author reply 1895. Epub 2012 Apr 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.41.9374DOI Listing
May 2012

The impact of thromboprophylaxis on cancer survival: focus on pancreatic cancer.

Expert Rev Anticancer Ther 2011 Apr;11(4):579-88

Unit of Medical Oncology, Department of Oncology and Haematology, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24126, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.10.184DOI Listing
April 2011

Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.

Nephron Clin Pract 2010 21;115(2):c154-60. Epub 2010 Apr 21.

Department of Medicine and Transplantation, Ospedali Riuniti, Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000312879DOI Listing
February 2011

Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management.

Thromb Res 2010 Apr;125 Suppl 2:S117-9

Unit of Medical Oncology, Department of Oncology/Haematology, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S004938481070028
Publisher Site
http://dx.doi.org/10.1016/S0049-3848(10)70028-1DOI Listing
April 2010

[Clinical role of palonosetron for patients receiving cisplatin-based chemotherapy].

Tumori 2008 Mar-Apr;94(2):suppl 23-5

Primario, Unità di Oncologia Medica, Ospedali Riuniti, Bergamo.

View Article

Download full-text PDF

Source
July 2008

Venous thromboembolism and pancreatic cancer: incidence, pathogenesis and clinical implications.

Onkologie 2008 Mar 8;31(3):129-35. Epub 2008 Feb 8.

Unit of Medical Oncology, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000113533DOI Listing
March 2008

Transforming growth factor-beta signaling and regulatory T cells.

J Clin Oncol 2007 Oct;25(29):4695-6; author reply 4696-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.2894DOI Listing
October 2007

Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer.

Expert Rev Anticancer Ther 2007 Jun;7(6):887-97

Unit of Medical Oncology, Ospedali Riuniti, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.7.6.887DOI Listing
June 2007